Welcome to our dedicated page for Janux Therapeutics news (Ticker: JANX), a resource for investors and traders seeking the latest updates and insights on Janux Therapeutics stock.
Janux Therapeutics, Inc. (Nasdaq: JANX) is a clinical-stage biopharmaceutical company whose news flow is closely tied to the progress of its tumor-activated immunotherapy platforms. The company regularly issues updates on its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) programs, making JANX news particularly relevant for followers of immuno-oncology and autoimmune disease research.
Investors and analysts tracking JANX can expect news items covering clinical trial updates for its lead TRACTr candidates, JANX007 and JANX008. Press releases describe Phase 1 data in metastatic castration-resistant prostate cancer for JANX007, including safety, radiographic progression-free survival and dosing strategies, as well as Phase 1 development of JANX008 in multiple advanced or metastatic solid tumors such as colorectal carcinoma, head and neck squamous cell carcinoma, several lung cancer subtypes, renal cell carcinoma, pancreatic ductal adenocarcinoma and triple-negative breast cancer.
Janux also issues R&D and pipeline communications, including R&D Day events that highlight preclinical advances in PSMA-TRACIr, TROP2-TRACTr and the CD19-ARM program. These announcements often discuss preclinical data, planned IND-enabling activities and anticipated timelines for moving candidates toward first-in-human trials. In addition, JANX news includes financial results and business highlights, where the company reports quarterly performance, research and development spending, and enrollment status for ongoing trials.
Another recurring category of news involves collaboration milestones, such as the clinical milestone payment triggered under Janux’s TRACTr collaboration with Merck. Corporate updates, including leadership appointments and strategic development commentary, also appear in the company’s releases. For a consolidated view of these developments, the JANX news page on Stock Titan aggregates earnings releases, clinical data announcements, R&D events and collaboration updates in one place for ongoing monitoring.
Janux Therapeutics (NASDAQ: JANX) will host a virtual event on December 1, 2025 at 4:30 PM ET where CEO David Campbell, Ph.D. will present updated clinical data for JANX007.
The presentation will emphasize Phase 1a dose-escalation results and secondarily cover Phase 1b expansion data in adult subjects with metastatic castration-resistant prostate cancer (mCRPC), followed by a live analyst Q&A. Registration is required to attend.
The release also summarizes Janux's development pipeline including JANX008 (EGFR TRACTr), additional CD3 TRACTr and CD28 TRACIr programs, a PSMA-TRACIr intended for combination use with JANX007, a TROP2-TRACTr, and a CD19-ARM program targeting autoimmune disease.
Janux Therapeutics (NASDAQ: JANX) reported third-quarter 2025 results and a business update on November 6, 2025. Key points: cash and short-term investments of $989.0 million as of September 30, 2025; ongoing enrollment in first-in-human Phase 1 trials for JANX007 (mCRPC) and JANX008 (advanced/metastatic solid tumors); additional JANX007 and JANX008 data expected in the fourth quarter of 2025.
Quarterly results: R&D expense $34.6M (Q3 2025) vs $18.6M (Q3 2024); G&A expense $10.6M vs $17.7M; net loss $24.3M vs $28.1M. Pipeline updates include multiple TRACTr, TRACIr and ARM candidates and planned clinic entries next year.
Janux Therapeutics (NASDAQ:JANX) reported Q2 2025 financial results and business updates, highlighting progress across its TRACTr, TRACIr, and ARM platforms. The company maintains a strong financial position with $996.0 million in cash and investments, down slightly from $1.03 billion at year-end 2024.
Key developments include ongoing enrollment in Phase 1 trials for JANX007 (targeting PSMA in mCRPC) and JANX008 (targeting EGFR in multiple solid tumors). Janux received a $10 million milestone payment from Merck following the first patient dosing in their lead collaboration program. The company's July R&D Day showcased new candidates including a PSMA-TRACIr, TROP2-TRACTr, and CD19-ARM for autoimmune diseases.
Q2 financial results showed increased R&D expenses of $34.7 million and a net loss of $33.9 million, reflecting expanded clinical development activities.
Janux Therapeutics (Nasdaq: JANX) has achieved a significant clinical milestone in its TRACTr collaboration with Merck, triggering a $10 million milestone payment. The achievement marks the dosing of the first patient in their collaborative program, stemming from their December 2020 partnership.
The company is advancing multiple clinical programs, including JANX007, a PSMA-targeting TRACTr in Phase 1 trials for mCRPC, and JANX008, an EGFR-targeting TRACTr being studied across multiple solid cancers. Janux is also developing additional CD3-based TRACTr and CD28-based TRACIr programs, including a PSMA-TRACIr and TROP2-TRACTr, alongside their first ARM platform program targeting CD19 for autoimmune diseases.
Janux Therapeutics (NASDAQ:JANX) showcased its pipeline progress during its virtual R&D Day, highlighting three key platforms: TRACTr, TRACIr, and ARM. The company announced advancement of its PSMA-TRACIr program, designed to enhance JANX007's efficacy in prostate cancer treatment, with clinical trials expected in H2 2026.
Janux introduced its TROP2-TRACTr program for multiple solid tumors, with IND-enabling activities planned for H2 2025. The company also revealed its novel CD19-ARM platform for autoimmune diseases, demonstrating promising preclinical results in B-cell depletion with first-in-human trials anticipated in H1 2026.
The company's pipeline includes two clinical-stage candidates: JANX007 for metastatic castration-resistant prostate cancer and JANX008 targeting EGFR in multiple solid cancers.
Janux Therapeutics (Nasdaq: JANX), a clinical-stage biopharmaceutical company, has announced a virtual R&D Day scheduled for July 24, 2025, at 1:30 PM PT. The event will showcase management presentations focusing on new preclinical pipeline candidates advancing to clinical trials.
The company specializes in novel immunotherapies using its proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms. Currently, Janux has two clinical candidates: JANX007, targeting PSMA in metastatic castration-resistant prostate cancer, and JANX008, targeting EGFR in multiple solid cancers. The company is also developing additional TRACTr and TRACIr programs at various development stages.
Janux Therapeutics (NASDAQ: JANX) has appointed Janeen Doyle, MBA as Chief Corporate and Business Development Officer. Doyle brings over 24 years of experience across biotech, pharma, and venture ecosystems. She joins from Flagship Pioneering, where she served as Senior Partner and SVP of Corporate Partnerships. Previously, she spent 15+ years at Bristol Myers Squibb and Celgene, most recently as SVP of Strategy & Business Development, overseeing 300+ strategic collaborations.
Janux is advancing its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms. The company has two clinical candidates: JANX007, targeting PSMA in metastatic castration-resistant prostate cancer, and JANX008, targeting EGFR in multiple solid cancers including colorectal carcinoma and lung cancer.
Janux Therapeutics (NASDAQ: JANX) reported its Q4 and full year 2024 financial results, highlighting significant clinical progress and strong financial position. The company presented positive Phase 1 trial data for PSMA-TRACTr JANX007 in prostate cancer, showing impressive results including 100% PSA50 decline rates and 50% objective response rate in treated patients.
Financial highlights include $1.03 billion in cash and investments as of December 31, 2024, bolstered by a $402.5 million capital raise in December 2024. The company reported increased R&D expenses of $68.4 million and G&A expenses of $41.0 million for 2024, with a net loss of $69.0 million.
Clinical progress continues with ongoing enrollment for both JANX007 and JANX008 trials, with updates anticipated in 2025 along with an R&D Day to discuss new programs.